'Fatal mi' presentation slideshows

Study rationale and design

Study rationale and design. EUROPA Study Investigators Lancet. 2003;362:782-788. ACE inhibition for secondary prevention of CAD. Rationale. Anti-atherosclerotic effects Plaque rupture reduction Improvement in vascular endothelial function Enhanced fibrinolysis

1.16k views • 90 slides

560 views • 41 slides

Preparazione Farmacologica alla PCI Primaria. Dalle Linee Guida ai Dati Degli Studi e dei Registri: sul Territorio

Convegno Area Emergenza-Urgenza ANMCO Preparazione alla PTCA nelle Sindromi Coronariche Acute Firenze, 23 Gennaio 2010. Preparazione Farmacologica alla PCI Primaria. Dalle Linee Guida ai Dati Degli Studi e dei Registri: sul Territorio. Leonardo De Luca, M.D., Ph.D., F.A.C.C.

565 views • 38 slides

Collaborative Atorvastatin Diabetes Study CARDS

Collaborative Atorvastatin Diabetes Study CARDS. Helen Colhoun, John Betteridge, Paul Durrington, Graham Hitman, Andrew Neil, Shona Livingstone, Margaret Thomason, Michael Mackness, Valentine Menys, John Fuller on behalf of the CARDS Investigators. CARDS The Rationale.

650 views • 35 slides

Analysis of Cardiovascular Thromboembolic Events With Etoricoxib

Analysis of Cardiovascular Thromboembolic Events With Etoricoxib. Joel Schiffenbauer, M.D. DAAODP, ODE V February 17, 2005. Etoricoxib. NDA indications include: OA, CLBP, RA, AS, acute gout, acute pain, dysmenorrhea Proposed doses: 60 and 90 mg chronically and 120 mg acutely

792 views • 31 slides

Outcome/ instruments selection

Outcome/ instruments selection. Wei-Chu Chie Preventive Medicine. A review of outcomes. Clinical Death: binary/Disease: any type/Utilization of care Functional/QOL Discomfort, QOL/Disability Perceptual Dissatisfaction/satisfaction, QOL Financial Behavioral

431 views • 27 slides

268 views • 26 slides

256 views • 25 slides

Disclosure

PCI in Patients Receiving Enoxaparin or UFH Following Fibrinolytic Therapy for STEMI: PCI ExTRACT-TIMI 25.

368 views • 23 slides

Myocardial Infarction and other Adverse events after Coronary Artery Bypass Surgery

Myocardial Infarction and other Adverse events after Coronary Artery Bypass Surgery. 4A Intern ??? 4A Intern ???. Introduction. 800 000 patients undergo CABG surgery worldwide each year Arterial grafting, refinements in cardioplegia, minimally invasive surgery, OPCAB

579 views • 23 slides

Baseline characteristics

Baseline characteristics. Registered 13 655. Not randomised 1 437. Randomised 12 218. Perindopril 6 110. Placebo 6 108. Completed 6 108. Completed 6 107. Patient flow. 141. 176. 57. 115. 134. 130. 2068. 94. 1772. 300. 277. 1251. 197. 2176. 209. 399. 65. 285. 830.

316 views • 20 slides

Can One Evaluate An Outcomes Claim Based On An Active Controlled Study?

Can One Evaluate An Outcomes Claim Based On An Active Controlled Study?. Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville, Maryland June 15, 2005. Sponsor Representatives And Introduction. Introduction and Objective

265 views • 20 slides

251 views • 15 slides

153 views • 15 slides

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators.

The diabetic sub study of. K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. Background. ACE inhibitor therapy of proven benefit in secondary prevention in myocardial infarction and heart failure

223 views • 14 slides

Oral Anticoagulation and Preventing Stent Thrombosis

298 views • 14 slides

Purpose

ESTEEM: Efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial infarction. Purpose

206 views • 7 slides

Background & objectives

124 views • 5 slides

Invasive vs. Selective strategy NSTEMI

Invasive vs. Selective strategy NSTEMI. Objective: To determine whether a routine invasive (RI) strategy reduces the long-term frequency of cardiovascular death or nonfatal MI using a meta analysis of individual data from FRISC II , ICTUS an RITA-3 trials.

168 views • 4 slides

CETP inhibition & cardiovascular endpoints comparison of DEFINE and ILLUMINATE

CETP inhibition & cardiovascular endpoints comparison of DEFINE and ILLUMINATE. The hazard ratios and 95% confidence intervals are shown. Primary endpoints.

161 views • 1 slides